Log in

NASDAQ:MYGNMyriad Genetics Stock Price, Forecast & News

$15.92
+0.42 (+2.71 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.26
Now: $15.92
$16.20
50-Day Range
$14.17
MA: $14.81
$15.92
52-Week Range
$9.24
Now: $15.92
$48.40
Volume1.92 million shs
Average Volume1.09 million shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
Myriad Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$851.10 million
Cash Flow$2.39 per share
Book Value$14.84 per share

Profitability

Net Income$4.60 million

Miscellaneous

Employees2,600
Market Cap$1.19 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by COVID-19 (Coronavirus)?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYGN stock has increased by 13.5% and is now trading at $15.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Myriad Genetics.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Myriad Genetics.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.10. The firm earned $164 million during the quarter, compared to analyst estimates of $167.38 million. Myriad Genetics had a positive return on equity of 1.95% and a negative net margin of 19.49%. Myriad Genetics's revenue for the quarter was down 24.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.46 earnings per share. View Myriad Genetics' earnings history.

What price target have analysts set for MYGN?

9 equities research analysts have issued 12-month price objectives for Myriad Genetics' shares. Their forecasts range from $10.00 to $36.00. On average, they expect Myriad Genetics' stock price to reach $21.85 in the next year. This suggests a possible upside of 37.2% from the stock's current price. View analysts' price targets for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

News coverage about MYGN stock has been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myriad Genetics earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMyriad Genetics.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a decline in short interest in May. As of May 15th, there was short interest totaling 8,750,000 shares, a decline of 7.0% from the April 30th total of 9,410,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is presently 7.1 days. Approximately 12.1% of the company's shares are sold short. View Myriad Genetics' Current Options Chain.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.71%), Baillie Gifford & Co. (12.03%), State Street Corp (5.49%), Disciplined Growth Investors Inc. MN (4.06%), Camber Capital Management LP (3.15%) and Morgan Stanley (1.52%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View institutional ownership trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., BlackRock Inc., Acadian Asset Management LLC, AQR Capital Management LLC, and Parametric Portfolio Associates LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, and Richard Bryan Riggsbee. View insider buying and selling activity for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Federated Hermes Inc., Invesco Ltd., FDx Advisors Inc., FDx Advisors Inc., State Street Corp, Disciplined Growth Investors Inc. MN, and CWM LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert. View insider buying and selling activity for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $15.92.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $1.19 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.